Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 22

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 8
Chunk 22
---
 total consideration of $558 million in cash, net of cash acquired.  The businesses acquired complement existing units of the Company’s Life Sciences segment.  The Company preliminarily recorded an aggregate of $305 million of goodwill related to these acquisitions.On December 6, 2023, the Company acquired Abcam plc (“Abcam”) for a cash purchase price of approximately $5.6 billion (the “Abcam Acquisition”).  Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research and diagnostics.  Abcam is now part of the Company’s Life Sciences segment.  Abcam generated revenues of approximately £362 million in 2022.  The acquisition of Abcam has provided and is expected to provide the Company additional sales and earnings opportunities in the proteomics sector.  The Company financed the Abcam Acquisition using cash on hand.  The Company recorded approximately $3.9 billion of goodwill related to the Abcam Acquisition.  During 2022, the Company acquired seven businesses for total consideration of $582 million in cash, net of cash acquired.  The businesses acquired complement existing units of each of the Company’s three segments.  The Company recorded an aggregate of $389 million of goodwill related to these acquisitions.The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition ($ in millions):202420232022Trade accounts receivable$15 $86 $4 Inventories1 94 7 Property, plant and equipment13 158 9 Goodwill305 3,851 389 Other intangible assets, primarily developed technology, trade names and customer relationships 419 2,146 200 Trade accounts payable(2)(32)(1)Deferred tax liabilities(59)(519)(10)Other assets and liabilities, net16 (49)(16)Net assets acquired708 5,735 582 Less: noncash consideration(150)(125)— Net cash consideration$558 $5,610 $582 The noncash consideration of $150 million and $125 million related to a 2024 and a 2023 acquisition, respectively, and were the result of the Company’s preexisting investments in acquired businesses.  Transaction-related costs for the Abcam Acquisition were $27 million for the year ended December 31, 2023.  The